Prospects for gene-engineered T cell immunotherapy for solid cancers.

Area of Science:

• Oncology
• Immunotherapy
• Cancer Genetics

Background:

• Adoptive transfer of receptor-engineered T cells, particularly chimeric antigen receptor (CAR) T cells, has demonstrated significant success in treating B cell leukemias and lymphomas.
• This success has spurred interest in applying similar strategies to epithelial cancers, which are the leading cause of cancer-related deaths globally.

Purpose of the Study:

• To provide a perspective on the challenges and necessary innovations for expanding the use of genetically redirected T cells to treat solid cancers.
• To highlight the limitations of current 'off-the-shelf' approaches targeting shared antigens and propose alternative strategies.

Main Methods:

• The study is a perspective piece, analyzing existing data and outlining future research directions.
• It critically evaluates the potential of T cell-based immunotherapies for solid tumors.

Main Results:

• Current receptor-engineered T cell therapies face significant hurdles for solid cancer treatment, including potential lethal toxicity due to on-target recognition of normal tissues.
• A scarcity of truly tumor-specific antigens shared across diverse tumor types limits the efficacy of universal 'off-the-shelf' approaches.

Conclusions:

• Expanding T cell-based therapies to solid cancers necessitates major innovations in technology, manufacturing, and regulatory frameworks.
• The development of autologous gene therapies that target private somatic mutations represents a promising direction for effectively treating the majority of patients with solid tumors.